You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 利好疊加 藥明生物(2269.HK)漲6%
格隆匯 03-29 10:00
格隆匯3月29日丨藥明生物(2269.HK)漲6.07%,報69港元,暫成交5.56億港元,總市值2906億港元。3月22日公司發佈2021年年報,全年實現營收102.9億元,同比增長83.3%;歸母淨利潤33.9億元,同比增長100.6%。大摩研報稱,藥明生物於內地生物藥外包市場保持領先地位,對公司2021至2024年的經調整純利複合年增長率料43%,而行業只有25%。對公司評級“增持”,以反映其高增長潛力及行業領先地位,目標價由80港元上調至86港元;瑞信維持其“跑贏大市”評級,估計今年收入將按年增長約43%。此外,昨日藥明生物獲南下資金淨買入3.84億港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account